skip to Main Content
Rafarma is a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, vaccines and specialty Pharma products in Europe & Asia. (307) 429-2029 Call Email
[stock-market-ticker symbols="RAFA" stockExchange="OTCMKTS" width="100%" palette="financial-light"]

Status Update to Shareholders from Rafarma Pharmaceuticals, Inc.

Nicosia, Cyprus, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) provides the following update to shareholders: The company is continuing its PCAOB auditing process, and, after input from accounting, legal, and business consultants, is changing the planned auditing years to 2020…

Read More

Rafarma’s Global Pharmaceutical Strategy At A Glance

Nicosia, Cyprus, May 18, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is an international biotechnological and pharmaceutical company that combines research centers and modern pharmaceutical production that meets international GMP standards. Rafarma Pharmaceuticals has consolidated and is in the process of consolidating…

Read More

Rafarma To Expand Proton Therapy Centers

Nicosia, Cyprus, May 07, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that RAFA is in active meetings with the City Scientific University of Istanbul (Turkey) ( to establish a nuclear medicine and proton therapy center at the university.…

Read More

Rafarma and Haifa Technopark Enter Talks for Joint Venture

Nicosia, Cyprus, April 30, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that on April 26, 2021, the company entered negotiations and formed an action plan with the Matam Technopark in Haifa, Israel ( to pursue joint development,…

Read More

Rafarma Embarks on Aggressive Global Partnerships Plan

Nicosia, Cyprus, March 04, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022. Given Rafarma’s current market position and the regulatory arena for the circulation of medicinal drugs in…

Read More

Letter To Shareholders from Chairman Ilya Shpurov

Nicosia, Cyprus, Nov. 09, 2020 (GLOBE NEWSWIRE) -- November 9, 2020 (GLOBE NEWSWIRE) Rafarma Pharmaceuticals, Inc. OTC:(RAFA) shares the following letter to shareholders from Chairman Ilya Shpurov: “It is my pleasure to provide the following update on Rafarma’s exciting future that should…

Read More

Rafarma Closes Biocogency Merger

Nicosia, Cyprus, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich (, Slavich Trading House, and related companies based in Spain, Ireland,…

Read More

Rafarma Adds Prestigious New Board Chairman Ilia Shpurov

Ljubljana, Slovenia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents, and entrepreneurial achievements in biotech. Most…

Read More

Rafarma Inks Deal For CBD-Infused Drink Product

Ljubljana, Slovenia, June 22, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce the finalization of the agreement with Destination Marketing Group Co. Ltd. Thailand. Under the agreement, Destination Marketing will provide outsourcing services for the production of CBD-infused…

Read More
Back To Top